文献速递炎症性肠病

中重度克罗恩病先进疗法健康相关生活质量改善的比较:网络Meta分析

Comparative Improvement in Health-Related Quality of Life With Advanced Therapies for Moderate-to-Severe Crohn's Disease: A Network Meta-Analysis.
PubMed 文献 · Am J Gastroenterol · 2025-01-29

本研究通过系统检索MEDLINE、Embase和Cochrane CENTRAL(至2023年12月),纳入评估获批先进疗法治疗成人中重度腔内型克罗恩病的随机对照试验,比较其对健康相关生活质量的影响。成对Meta分析显示,先进疗法在诱导期和维持期均与IBDQ评分改善相关;网络Meta分析中,乌帕替尼45 mg在诱导期、英夫利西单抗10 mg/kg在维持期分别排名第一。

要点

  • 先进疗法在诱导期与IBDQ评分改善相关(MD 16.07,95%CI 12.59-19.54)。
  • 乌帕替尼45 mg在诱导期IBDQ变化排名第一(MD 23.10,95%CI 14.41-31.78,P-score 0.86)。
  • 英夫利西单抗10 mg/kg在维持期IBDQ变化排名第一(MD 24.91,95%CI 12.99-36.83,P-score 0.90)。

核心结论

  • 先进疗法在诱导期和维持期均与健康相关生活质量改善相关。
  • 乌帕替尼45 mg和英夫利西单抗10 mg/kg分别在诱导期和维持期排名最高。

研究设计与样本

  • 系统检索MEDLINE、Embase和Cochrane CENTRAL从建库至2023年12月。
  • 纳入评估获批先进疗法治疗成人中重度腔内型克罗恩病的随机对照试验。
  • 检索策略共纳入34条符合入选标准的记录。
  • 采用成对随机效应Meta分析和随机效应频率学派网络Meta分析,竞争干预措施用P-score排名。

主要发现

  • 成对Meta分析中,先进疗法在诱导期与IBDQ评分改善相关(MD 16.07,95%CI 12.59-19.54)。
  • 网络Meta分析中,乌帕替尼45 mg在诱导期IBDQ变化排名第一(MD 23.10,95%CI 14.41-31.78,P-score 0.86)。
  • 维持期研究中,成对Meta分析显示先进疗法与IBDQ评分显著改善相关(MD 12.72,95%CI 10.47-14.97)。
  • 网络Meta分析中,英夫利西单抗10 mg/kg在维持期IBDQ变化排名第一(MD 24.91,95%CI 12.99-36.83,P-score 0.90)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The comparative efficacy of advanced therapies to improve health-related quality of life (HR-QoL) in Crohn's disease (CD) is unknown. We aimed to compare the impact of approved advanced therapies for moderate-to-severe CD on HR-QoL. METHODS: We searched MEDLINE, Embase, and Cochrane CENTRAL from inception to December 2023. We included randomized controlled trials that assessed approved advanced therapies for the treatment of adults with moderate-to-severe luminal CD. The primary outcome was change from baseline in the Inflammatory Bowel Disease Questionnaire (IBDQ). Pairwise random-effects meta-analyses were conducted, and we reported results as mean differences (MDs) for continuous outcomes and risk ratios for binary outcomes, with corresponding 95% confidence intervals (CIs). A random-effects frequentist network meta-analysis was conducted, and the competing interventions were ranked using the P-score. RESULTS: Our search strategy included 34 records that fulfilled our eligibility criteria. In pairwise meta-analysis, advanced therapies were associated with improvements in IBDQ score (MD 16.07, 95% CI 12.59-19.54) after induction. In network meta-analysis, upadacitinib 45 mg ranked first for change in IBDQ after induction (MD 23.10, 95% CI 14.41-31.78, P-score 0.86). For maintenance studies, advanced therapies showed a significant improvement in IBDQ score in pairwise meta-analysis (MD 12.72, 95% CI 10.47-14.97). Infliximab 10 mg/kg ranked first for change in IBDQ after maintenance (MD 24.91, 95% CI 12.99-36.83, P-score 0.90). DISCUSSION: Advanced therapies were associated with improvements in HR-QoL after induction and maintenance. Upadacitinib 45 mg and infliximab 10 mg/kg ranked highest after induction and maintenance, respectively.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Olivera PA, Parks ML, Zubiaurre I, et al. Comparative Improvement in Health-Related Quality of Life With Advanced Therapies for Moderate-to-Severe Crohn's Disease: A Network Meta-Analysis. Am J Gastroenterol. 2025. PMID: 39878444. doi:10.14309/ajg.0000000000003333

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。